论文部分内容阅读
绝经激素治疗(MHT)与乳腺癌的关系一直受到密切关注。迄今为止,健康妇女进行绝经激素治疗发生乳腺癌的风险仍未明确,但至少可以肯定,即使有风险,其绝对值也很小,年发生率小于0.1%,低于生活方式对乳腺癌风险的影响。影响该风险的因素很多,如不同的绝经激素治疗方案、孕激素种类、治疗时间的长短,甚至启动时机可能也有影响。增加的风险主要与孕激素种类及治疗时间有关。文章还介绍了乳腺癌1、2号基因阳性患者中MHT对其乳腺癌风险的影响。
The relationship between menopausal hormone therapy (MHT) and breast cancer has been closely watched. To date, the risk of developing breast cancer in healthy women with menopausal hormone therapy is not yet known, but at least the absolute absolute value is small, at a risk of less than 0.1%, below the lifestyle risk of breast cancer influences. Many factors affect the risk, such as different treatment options for menopause hormone, type of progestin, the length of treatment time, and even start-up timing may also have an impact. The increased risk is mainly related to the type of progestin and the duration of treatment. The article also describes the impact of MHT on breast cancer risk in patients with positive breast cancer # 1 and # 2.